Risk evaluation and mitigation strategies: a focus on belatacept.

Sam, Teena; Gabardi, Steven; Tichy, Eric M

Sam, Teena; Gabardi, Steven; Tichy, Eric M.

Affiliation

Sam T; Yale-New Haven Hospital, New Haven, CT, USA. teena.sam@ynhh.org

Prog Transplant ; 23(1): 64-70, 2013 Mar.

Article in En | MEDLINE | ID: mdl-23448823

Subject(s)

Immunoconjugates/adverse effects; Immunosuppressive Agents/adverse effects; Organ Transplantation; Pharmacovigilance; Risk Management/methods; Abatacept; Central Nervous System Infections/chemically induced; Drug Labeling; Humans; Leukoencephalopathy, Progressive Multifocal/chemically induced; Lymphoproliferative Disorders/chemically induced; Patient Education as Topic; Registries; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Risk Management / Organ Transplantation / Immunoconjugates / Pharmacovigilance / Immunosuppressive Agents Type of study: Etiology_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Country/Region as subject: America do norte Language: En Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google